However, further studies are needed to elucidate whether such specific transcriptional modulation of RXRα, LXRβ receptors, and the ABCA-1 transporter can be translated into tangible clinical benefits, particularly in inflammatory diseases such as CKD. Here, RXRA is linked to chronic kidney disease.